What is Anika Therapeutics's accounts payable?

Anika Therapeutics (ANIK) reported accounts payable of -$575K in Q2 2026.

How has Anika Therapeutics's accounts payable changed year-over-year?

Anika Therapeutics's accounts payable increased by 48.3% year-over-year, from -$1.11M to -$575K.

What is the long-term trend for Anika Therapeutics's accounts payable?

Over 3 years (2021 to 2025), Anika Therapeutics's accounts payable has grown at a -66.3% compound annual growth rate (CAGR), from -$1.1M to $42K.

Anika Therapeutics ANIK Accounts Payable

Accounts Payable at other companies

Globus MedicalGMED

——

Envista Holdings CorporationNVST

——

Other financials

Income statement

See full

Revenue$32.6M+15.6%

Net income$3.3M+183%

EPS (diluted)$0.24—

Balance sheet

See full

Cash & equivalents$38.4M-27.8%

Total debt$25.7M+1.2%

Total equity$137.3M-7.0%

Total assets$183.5M-2.2%

Cash flow

See full

Operating cash flow-$684.0K-262%

CapEx$1.4M-1.2%

Free cash flow-$2.1M-28.8%

Valuation

See full

Market cap$199.85M+23.0%

P/S1.7×-0.1×

Profitability

See full

Net margin-3.4%-1.6pp

FCF margin0.5%—

Returns & leverage

See full

Return on equity-2.9%-1.4pp

Debt / equity0.2×0.0×

Current ratio4.5×-1.7×

Where this comes from

Reported directly by Anika Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: Anika Therapeutics’s 8-K, filed July 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Anika Therapeutics's accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Anika Therapeutics's accounts payable?: Anika Therapeutics (ANIK) reported accounts payable of -$575K in Q2 2026.
How has Anika Therapeutics's accounts payable changed year-over-year?: Anika Therapeutics's accounts payable increased by 48.3% year-over-year, from -$1.11M to -$575K.
What is the long-term trend for Anika Therapeutics's accounts payable?: Over 3 years (2021 to 2025), Anika Therapeutics's accounts payable has grown at a -66.3% compound annual growth rate (CAGR), from -$1.1M to $42K.